Patents Assigned to Shanghai Acebright Pharmaceuticals Group Co., Ltd.
  • Patent number: 11414388
    Abstract: The present invention relates to a crystal form of 3-(4-methyl-1H-imidazol-1-yl)-5-trifluoromethylaniline monohydrochloride and the use thereof. Specifically, disclosed are a crystal form A of a monohydrochloride anhydrous substance of 3-(4-methyl-1H-imidazol-1-yl)-5-trifluoromethylaniline monohydrochloride, a method for preparing the crystal form A and the use of the crystal form in the synthesis of nilotinib. The crystal form A of the present invention has good stability and purity, and can be directly used in the preparation and production of nilotinib. The method for preparing nilotinib in the present invention is easy to operate and has high industrial application value.
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: August 16, 2022
    Assignees: Arizest (Shanghai) Pharmatech Co., Ltd., Jiangsu Xidi Pharmaceuticals Co., Ltd., Shanghai Acebright Pharmaceuticals Group Co., Ltd.
    Inventors: Deliang Niu, Bojun Ma, Zhanqun Zhu, Qiang Wan
  • Patent number: 9522934
    Abstract: Provided are acetaic abiraterone trifluoroacetate, a preparation method and an application of same. The acetaic abiraterone trifluoroacetate is obtained through a salt-forming reaction between acetaic Abiraterone and trifluoroacetic acid. The acetaic abiraterone trifluoroacetate undergoes self-purification through recrystallization, and dissociation and recrystallization are performed on the purified abiraterone acetate trifluoroacetate, so that the obtained acetaic abiraterone has a high purity, a high yield and stable quality, and is capable of meeting the requirement for mass production of acetaic abiraterone.
    Type: Grant
    Filed: February 20, 2013
    Date of Patent: December 20, 2016
    Assignees: Shanghai Cdymax Pharmaceuticals Co., Ltd., Jiangsu Cdymax Pharmaceuticals Co., Ltd., Shanghai Acebright Pharmaceuticals Group Co., Ltd.
    Inventors: Xiaoxia An, Chengjun Huang, Fengwang Mao